Clinical Trial Update: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia [Phase 3]

View source ↗

Summary

A Phase 3 study in Waldenström's macroglobulinemia completed evaluating the first-line DRC regimen with or without bortezomib, reporting efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: University of Ulm | Conditions: Waldenström's Macroglobulinemia | Phase 3 | Status: COMPLETED